{"id":4727,"date":"2025-10-06T14:15:02","date_gmt":"2025-10-06T11:15:02","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4727"},"modified":"2025-10-06T14:51:39","modified_gmt":"2025-10-06T11:51:39","slug":"zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd\/","title":{"rendered":"Zydus Lifesciences recebe aprova\u00e7\u00e3o FDA para Deflazacort para tratar DMD"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Na segunda-feira, 6 de outubro, a empresa farmac\u00eautica Zydus Lifesciences anunciou que o FDA havia dado a aprova\u00e7\u00e3o final para sua suspens\u00e3o oral de deflazacorte na dose de 22,75 mg\/mL. O produto cont\u00e9m 22,75 mg\/mL de suspens\u00e3o oral de Emflaza em forma gen\u00e9rica.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">O que \u00e9 Deflazacort (Emflaza)?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pacientes com cinco anos de idade ou mais com Distrofia Muscular de Duchenne (DMD) podem ser tratados com deflazacorte suspens\u00e3o oral. Como membro da classe dos esteroides, o medicamento ajuda a reduzir a inflama\u00e7\u00e3o e a acalmar um sistema imunol\u00f3gico hiperativo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O produto ser\u00e1 produzido em Doppel, It\u00e1lia, de acordo com a Zydus. Esta aprova\u00e7\u00e3o eleva o n\u00famero total de aprova\u00e7\u00f5es do grupo para 424.<\/p>","protected":false},"excerpt":{"rendered":"<p>On Monday, October 6, pharmaceutical company Zydus Lifesciences announced that the FDA has given its final approval for its oral suspension of deflazacort at a dose of 22.75 mg\/mL. The product contains 22.75 mg\/mL of Emflaza oral suspension in a generic form. What is Deflazacort (Emflaza)? Patients five years of age and older with Duchenne [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4728,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[211,428,88,429],"class_list":["post-4727","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-deflazacort","tag-emflaza","tag-fda","tag-zydus-lifesciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4727"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4727\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4728"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}